TMS.2.3.2004

Transfusionsmedicinske Standarder. Version 2.0 R.11
Transport and international exchange of substances of human
origin. Recommendation No. (79) 5.
Blood products for the treatment of haemophiliacs. Recommendation
No. R (80) 5.
Antenatal administration of anti-D immunoglobulin. Recommendation
No. R (81) 5.
Assessment of the risks of transmitting infectious diseases by
international transfer of blood, its components and derivatives.
Recommendation No. R (81) 14.
Preventing the possible transmission of acquired immune deficiency
syndrome (AIDS) from affected blood to patients receiving
blood or blood products. Recommendation No. R (83) 8.
Prevention of the transmission of malaria by blood transfusion.
Recommendation No. R (84) 6.
Study on the current position of training programmes for future
specialists in blood transfusion in Council of Europe member
states and in Finland. Recommendation No. R (85) 5.
On the Screening of blood donors for the presence of Aids
markers. Recommendation No. R (85) 12.
Guidelines for the preparation, quality control and use of fresh
frozen plasma (FFP). Recommendation No. R (86) 6.
Common European public health policy to fight the acquired
immunodeficiency syndrome (AIDS). Recommendation No. R
(87) 25.
Responsibilities of health authorities in the field of blood transfusion.
Recommendation No. R (88) 4.
Ethical issues of HIV infection in the health care and social
settings. Recommendation No. R (89) 14.
Medical research on human beings. Recommendation No. R (90)
3.
Plasma products and European self-sufficiency. Recommendation
No. R (90) 9.
Clinical trials involving the use of components and fractionated
products derived from human blood or plasma. Recommendation
No. R (93) 4.
Protection of the health of donors and recipients in the area of
blood transfusion Recommendation No. R (95) 14.
Preparation, use and quality assurance in blood components.
Recommendation No R (95) 15
© 1994-2004 Dansk Selskab for Klinisk Immunologi